



MAYNE PHARMA LAUNCHES CLOZAPINE TABLETS IN THE US

9 Nov 2017, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of the full range of clozapine tablets (25mg, 50mg, 100mg and 200mg) in the United States. Clozapine tablets are a generic alternative to Clozaril®, indicated as an antipsychotic.

Mayne Pharma's CEO Scott Richards said, "The launch of the full range of Clozapine tablets is our 6th product launch in 2017 and will further diversify our product offering. This product which is currently manufactured by Teva Pharmaceuticals Industries Limited, will ultimately be manufactured at our facility in Greenville, North Carolina and benefit from the investment underway to expand capacity. The new solid oral dose manufacturing facility is poised to open in early 2018 and will quadruple the Company's U.S. manufacturing capacity to well over 1 billion doses, and importantly introduces significant new capacity to manufacture high potent compounds and new capability to manufacture modified-release bead/pellet products."

Mayne Pharma directly markets more than 55 products and has a growing pipeline of more than 40 drug products targeting U.S. markets with QuintilesIMS sales greater than \$6.5 billion. According to QuintilesIMS, annual US sales of clozapine tablets were approximately US\$125 million for the 12 months ending 31 August 2017.

For further information contact:

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in formulation complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds.

Clozaril® is a registered trademark of Novartis AG Corporation.